Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesAsset Writedowns and ImpairmentCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in IntangiblesChange in InventoryChange in ReceivablesDeferred TaxesDepreciation & Amortization (CF)Depreciation and DepletionExchange Rate EffectFree Cash FlowGains from Investment SecuritiesLong-Term Debt RepaymentsNet Cash FlowNet IncomeOther Working Capital ChangesOther financing activitiesSales of Property, Plant and EquipmentShare-based CompensationShares IssuedShort-Term Debt issuances
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Cytek Biosciences (CTKB) Change in Receivables (2020 - 2025)

Cytek Biosciences (CTKB) has disclosed Change in Receivables for 6 consecutive years, with $6.1 million as the latest value for Q4 2025.

  • For the quarter ending Q4 2025, Change in Receivables fell 34.12% year-over-year to $6.1 million, compared with a TTM value of -$368000.0 through Dec 2025, down 106.78%, and an annual FY2025 reading of -$368000.0, down 106.78% over the prior year.
  • Change in Receivables was $6.1 million for Q4 2025 at Cytek Biosciences, up from $587000.0 in the prior quarter.
  • Across five years, Change in Receivables topped out at $9.3 million in Q4 2024 and bottomed at -$6.4 million in Q1 2025.
  • Average Change in Receivables over 5 years is $2.2 million, with a median of $2.4 million recorded in 2022.
  • The sharpest move saw Change in Receivables crashed 683.33% in 2023, then surged 3647.15% in 2024.
  • Year by year, Change in Receivables stood at $720000.0 in 2021, then soared by 1006.11% to $8.0 million in 2022, then tumbled by 103.3% to -$263000.0 in 2023, then soared by 3647.15% to $9.3 million in 2024, then tumbled by 34.12% to $6.1 million in 2025.
  • Business Quant data shows Change in Receivables for CTKB at $6.1 million in Q4 2025, $587000.0 in Q3 2025, and -$652000.0 in Q2 2025.